Disco's no basher.  Just an honest question.  Personally, I wouldn't value POET based on revenues (small) or earnings (negative) yet, or anytime soon.  It's all speculative value, and a lot less than we used to have.

This is not unusual as time passes, as morre and more skepticism creeps in relative to achievement  of the kind of success we're looking for.   Happens with biotechs all the time.